Gland Pharma has informed that, Xiao Le has been appointed as the Chief Investment Officer of Gland Pharma International, (‘Gland Singapore’) the Wholly-owned subsidiary of the Company, effective November 09, 2026. Xiao Le will be responsible for exploring various investment opportunities and to improve M&A capability for Gland in the United States of America, China, Singapore and other countries. Xiao Le shall be reporting to the CEO of Gland Singapore. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in Annexure-A enclosed.
The above information is a part of company’s filings submitted to BSE.